1-(2,6-difluoro-3-nitrophenyl)ethanone | 91188-91-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2,6-difluoro-3-nitrophenyl)ethanone
• 英文别名: 2',6'-difluoro-3'-nitro-acetophenone
• CAS: 91188-91-9
• 化学式: C₈H₅F₂NO₃
• 分子量: 201.129
• InChiKey: CGCFAZUWFVSIJD-UHFFFAOYSA-N

物化性质

• 沸点：
  245.2±35.0 °C(Predicted)
• 密度：
  1.424±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(2,6-difluoro-3-nitrophenyl)ethanone 在 镍 盐酸 、 正丁基锂 、 氢气 作用下， 以 乙醇 、 溶剂黄146 为溶剂， -78.0~50.0 ℃ 、344.73 kPa 条件下， 反应 67.5h， 生成 1-(7-fluoro-3,4-dihydro-3-methyl-2H-1,4-benzoxazine-8-yl)ethanone
  参考文献：
  名称：

  新的7-取代的喹诺酮类抗菌剂。1-乙基-1,4-二氢-4-氧代-7-（2-噻唑基和4-噻唑基）-3-喹啉羧酸的合成

  摘要：

  一系列1-乙基-1,4-二氢-4-氧代-7-（4-噻唑基）-3-喹啉羧酸和1-乙基-1,4-二氢-4-氧代-7-（2-噻唑基制备）-3-喹啉羧酸。还制备了10- [2-（氨基甲基）-4-噻唑基] -9-氟-2,3-二氢-3-甲基-7-氧代-7 H-吡啶基[1,2,3- de ] [1 ，4]苯并恶嗪-6-羧酸。发现在噻唑部分具有碱性胺取代基的类似物具有抗菌活性。

  DOI：

  10.1002/jhet.5570240604
• 作为产物：
  描述：

  2,6-二氟苯腈 在 硫酸 、 硝酸 作用下， 以 乙醚 为溶剂， 反应 2.75h， 生成 1-(2,6-difluoro-3-nitrophenyl)ethanone
  参考文献：
  名称：

  新的7-取代的喹诺酮类抗菌剂。1-乙基-1,4-二氢-4-氧代-7-（2-噻唑基和4-噻唑基）-3-喹啉羧酸的合成

  摘要：

  一系列1-乙基-1,4-二氢-4-氧代-7-（4-噻唑基）-3-喹啉羧酸和1-乙基-1,4-二氢-4-氧代-7-（2-噻唑基制备）-3-喹啉羧酸。还制备了10- [2-（氨基甲基）-4-噻唑基] -9-氟-2,3-二氢-3-甲基-7-氧代-7 H-吡啶基[1,2,3- de ] [1 ，4]苯并恶嗪-6-羧酸。发现在噻唑部分具有碱性胺取代基的类似物具有抗菌活性。

  DOI：

  10.1002/jhet.5570240604

文献信息

• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• [EN] 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS<br/>[FR] 3,4-DIARYLPYRAZOLES UTILISÉS COMME INHIBITEURS DE PROTÉINE KINASE
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2010010154A1

  公开（公告）日：2010-01-28

  3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  公开了规范中定义的式(I)的3,4-二芳基吡唑衍生物及其药用盐，其制备方法和包含它们的药物组合物；发明的化合物可能在治疗中对治疗与蛋白激酶活性失调相关的疾病，如癌症，具有用处。
• [EN] ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES<br/>[FR] DERIVES DE 2-(SULFO-PHENYL)-AMINOTHIAZOLE ANTIPROLIFERATIFS
  申请人：PFIZER

  公开号：WO2004072070A1

  公开（公告）日：2004-08-26

  Aminothiazole compounds substituted with sulfur-containing groups are represented by the Formula (I), and their pharmaceutically acceptable salts, prodrugs, active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.

  含有硫基取代基团的氨基噻唑化合物由化学式(I)表示，并描述了它们的药用可接受盐、前药、活性代谢物以及所述代谢物的药用可接受盐。这些药物调节和/或抑制细胞增殖和蛋白激酶活性，可用作治疗恶性肿瘤和其他疾病的药物。
• Antibacterial agents
  申请人：Warner-Lambert Co.

  公开号：US04638067A1

  公开（公告）日：1987-01-20

  Novel naphthyridine-, quinoline- and benzoxazine-carboxylic acids as antibacterial agents are described as well as methods for their manufacture, formulation, and use in treating bacterial infections including the description of certain novel intermediates used in the manufacture of the antibacterial agents.

  描述了新型萘啉基、喹啉基和苯并噁嗪基羧酸作为抗菌剂，以及它们的制造、配方和用于治疗细菌感染的方法，包括用于制造抗菌剂的某些新型中间体的描述。
• [EN] IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS DE DIOXYDE D'IMINOTHIADIAZINE COMME INHIBITEURS DE BACE, COMPOSITIONS ET LEUR UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011044181A1

  公开（公告）日：2011-04-14

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-,L2-, and L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些亚氨基噻二嗪二氧化物化合物，包括化合物式(I)的化合物和其立体异构体，以及所述化合物立体异构体的药学上可接受的盐，其中每个R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、L2-和L3-都是独立选择并在此定义。该发明的新型亚氨基噻二嗪二氧化物化合物出人意料地表现出具有优势的BACE抑制剂特性和/或用于治疗和预防与β-淀粉样蛋白（Aβ）产生相关的各种病理的特性。还公开了包括一种或多种这样的化合物（单独和与一种或多种其他活性剂的组合）的制药组合物，并揭示了在治疗与淀粉样β（Aβ）蛋白相关的病理，包括阿尔茨海默病中使用它们的方法。